APT Pharmaceuticals is a technology company.
APT Pharmaceuticals has raised $32.0M across 1 funding round.
APT Pharmaceuticals has raised $32.0M in total across 1 funding round.
APT Pharmaceuticals has raised $32.0M in total across 1 funding round.
APT Pharmaceuticals's investors include Canaan Partners.
APT Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing inhaled therapeutics for inflammatory diseases, transplantation, and thrombotic conditions using human apyrase technology.[2][3][4] It targets cardiovascular and neurological diseases, with its lead candidate APT-102 aimed at preventing platelet aggregation to treat heart attacks, strokes, acute lung injury, and pulmonary arterial hypertension, while minimizing hemorrhage risks.[3][4] The company serves patients with orphan indications and seeks out-licensing partners, with its asset Phase 2-ready and cGMP drug substance available.[3]
Note: Search results reveal multiple entities with similar names, including APT Medical (a medical device manufacturer founded in 2002)[1] and APT Therapeutics (a related biopharma developing apyrase therapies).[3][4] This overview centers on APT Pharmaceuticals as the queried subject, distinct from these but overlapping in biotech focus.[2]
APT Pharmaceuticals, Inc. was founded to advance inhaled therapeutics specifically for inflammatory diseases and transplantation, though exact founding year details are limited in available data.[2] It shares roots with APT Therapeutics, Inc., incorporated in 2001 as a privately held biopharmaceutical company based in Naperville, Illinois, which has driven development of human apyrase (e.g., APT-102) for thrombotic diseases.[3][4] Key pivots include shifting focus to cardiovascular and neurological applications, with early emphasis on Phase 2-ready assets for orphan indications amid out-licensing efforts.[3] No specific founders are named, but the company's emergence ties to research in platelet aggregation inhibitors, building traction through clinical readiness and partnerships like BIO International Convention exhibitors.[3]
APT Pharmaceuticals rides the wave of precision biopharma targeting thrombotic and inflammatory diseases, where platelet aggregation drives major killers like heart attacks and strokes.[4] Timing aligns with maturing pipelines in cystic fibrosis and related respiratory conditions, fueled by venture philanthropy and VC resurgence in orphan drugs.[5] Market forces favoring it include rising demand for hemorrhage-safe antithrombotics amid aging populations and post-pandemic cardiovascular risks, plus regulatory incentives for Phase 2-ready orphan assets.[3] It influences the ecosystem by advancing apyrase tech, potentially enabling partnerships that accelerate therapies in a $100B+ cardiovascular market.
Next steps likely involve securing out-licensing deals for APT-102's initial orphan trials, leveraging its Phase 2 readiness to attract big pharma amid biotech funding recovery.[3] Trends like AI-driven drug discovery and mRNA-adjacent anti-thrombotics will shape its path, with influence evolving through potential acquisitions if hemorrhage-minimizing data shines in trials. As a specialized player in thrombotic innovation, APT Pharmaceuticals could redefine safer interventions, tying back to its core mission of transforming apyrase into lifesaving medicine.[4]
APT Pharmaceuticals has raised $32.0M across 1 funding round. Most recently, it raised $32.0M Series B in September 2008.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2008 | $32.0M Series B | Canaan Partners |